ML
Insider
Mark Lappe
Chief Executive OfficerMark Lappe (Chief Executive Officer) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Inhibrx Biosciences, Inc. (INBX). The largest single filing was $2.6M of INBX (24,500 sh across 5 lots, as filed), executed Sep 8. The median gap between execution and disclosure was 0 days.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
purchases not yet priced
Delay-adjustediThe same average, entered at disclosure dates
–
purchases not yet priced
Filings, ttm
1
1 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$2.6M
shares × price, as filed
Last traded
Sep 8
Filed Sep 8
Median ADV $33.6M across their filed names
100% of their measured filings could not be priced (delisted or unquoted names). The returns above cover only what still trades.
Open performance→Volume by month
Buys $2.6M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
INBX
Inhibrx Biosciences, Inc.
INBX · 1 buy · 0 sells
1 filing
Recent filings
INBXPURCHASE
Inhibrx Biosciences, Inc.
View filing →
$2.6M24,500 sh across 5 lots
Exec Sep 8
Filed Sep 8 · 4:04 PM ET INBXPURCHASE Inhibrx Biosciences, Inc. View filing → $629K
40,000 sh across 2 lots
Exec Sep 12 2024
Filed Sep 16 2024 · 5:30 PM ET INBXPURCHASE Inhibrx Biosciences, Inc. View filing → $671K
44,000 sh across 3 lots
Exec Sep 6 2024
Filed Sep 10 2024 · 5:30 PM ET